With effect from June 09, 2023, the subscription rights in Nasdaq will be traded on the list for Equity rights. Trading will continue up until and including June 20, 2023. Instrument: Subscription units Short name: XSPRAY UR Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0020355659 Order book ID: 295193 Market Segment: OMX STO Eq.rights,Subs.Opt, Int. shares Tick Size: MiFID II tick size table With effect from June 09, 2023, the subscription rights in Nasdaq will be traded on the list for Equity rights. Trading will continue until further notice. Instrument: Subscription units Short name: XSPRAY BTU Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0020355667 Order book ID: 295194 Market Segment: OMX STO Eq.rights,Subs.Opt, Int. shares Tick Size: MiFID II tick size table For further information concerning this exchange notice please contact Issuer Surveillance , telephone +46 8 405 70 50, or iss@nasdaq.com Nasdaq Stockholm AB
Nasdaq Stockholm AB: Listing of subscription units and paid subscription units of XSpray Pharma AB
© 2023 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2023 | October-December 2023, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -54,513 thousand (-55,220)Earnings per share before dilution amounted to SEK -1.85 (-2.48)Cash flow... ► Artikel lesen | |
| 12.02. | After rejection, FDA re-accepts Xspray's application for would-be rival to BMS' Sprycel | ||
| 12.02. | FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc - PDUFA Date set to 31 July 2024 | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma's New Drug Application (NDA) for Dasynoc, following... ► Artikel lesen | |
| 21.11.23 | Xspray Pharma AB: Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage | XS003, an amorphous non-crystalline nilotinib, designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®), is the second protein kinase... ► Artikel lesen | |
| 08.11.23 | Xspray Pharma AB: DASYNOC Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL Uptake is Significantly More Impaired than Previously Understood | DASYNOC (Xspray's low dose, amorphous, non-crystalline, dasatinib) avoids interactions with proton pump inhibitors (PPIs), making it potentially the first and only dasatinib to provide patients... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
